0001664710-26-000018
SEC filingKeros Therapeutics, Inc. reported a significant financial turnaround for fiscal year 2025, driven by its exclusive license agreement with Takeda. The company generated total revenue of $244.1 million, a substantial increase from $3.6 million in the prior year, primarily from a $200.0 million upfront payment and a $10.0 million development milestone under the Takeda Agreement, along with $38.5 million in service revenue. This resulted in net income of $87.0 million, a sharp reversal from a net loss of $187.4 million in 2024. Operating income was $67.6 million, compared to an operating loss of $210.8 million in the prior year. The company ended the year with $287.4 million in cash and cash equivalents and expects its existing capital to fund operations into the first half of 2028. The financial performance was heavily dependent on the one-time Takeda payment, while core research and development expenses for its lead candidates, rinvatercept and elritercept, continued.
Keros Therapeutics achieved a transformative financial year in 2025, reporting its first annual profit. Total revenue was $244.1 million, a massive increase from $3.6 million in 2024. This was driven by $205.4 million in license revenue from the Takeda Agreement (a $200 million upfront payment and a $10 million development milestone) and $38.7 million in service and other revenue. Net income was $87.0 million, a stark reversal from a net loss of $187.4 million in the prior year. Operating income was $67.6 million compared to an operating loss of $210.8 million in 2024. The company's profitability was entirely attributable to the one-time collaboration revenue, as it remains a clinical-stage company with no product sales. Research and development expenses decreased by $44.0 million to $129.6 million, primarily due to reduced spending on cibotercept (following trial termination) and the transition of elritercept clinical activities to Takeda.
Revenue for FY2025 consisted exclusively of collaboration and licensing payments. License revenue of $205.4 million was recognized from the Takeda Agreement. Service and other revenue of $38.7 million was primarily related to a transition services agreement with Takeda, with a minor component ($0.2 million) from agreements with Hansoh. In the prior year, revenue of $3.6 million was solely from the Hansoh Agreement ($3.0 million license revenue and $0.6 million service/other). The document does not disclose revenue by geographic segment or product, as the company has no commercial products. Future revenue is contingent on achieving further development, regulatory, and sales milestones under the Takeda and Hansoh agreements, as well as potential royalty streams.
The company's operating margin for 2025 was 27.7%, derived from operating income of $67.6 million on revenue of $244.1 million. This positive margin represents a complete turnaround from significant operating losses in prior years. The improvement in profitability was driven by the high-margin license revenue from Takeda, which had minimal direct cost of revenue. Operating expenses decreased by 17.7% to $176.5 million. Research and development expenses fell by 25.3% to $129.6 million due to strategic reprioritization, including deprioritizing cibotercept and transitioning elritercept work. General and administrative expenses increased by 15.0% to $46.8 million, attributed to higher professional fees. The cost structure remains heavily weighted toward R&D as the company advances rinvatercept and other preclinical programs.
Net cash provided by operating activities was $107.5 million in 2025, a positive shift from $160.9 million used in 2024, driven by net income. Key adjustments included $28.7 million in stock-based compensation. Net cash used in investing activities was minimal at $1.6 million for property and equipment. Financing activities used $378.5 million, primarily for the repurchase of $375.0 million in treasury stock via direct agreements and a tender offer. The balance sheet shows total assets of $338.0 million. Cash and cash equivalents were $287.4 million, down from $559.9 million (including restricted cash) at the end of 2024, largely due to the share repurchases. Total liabilities were low at $34.9 million, and stockholders' equity was $303.1 million. Management believes existing cash will fund operations into the first half of 2028.
The company's forward-looking statements indicate it expects to continue incurring significant operating losses for the foreseeable future as it advances its clinical pipeline. Key near-term priorities include commencing Phase 2 trials for rinvatercept in Duchenne muscular dystrophy (Q2 2026) and engaging regulators for a Phase 2 trial in ALS (H2 2026). Capital requirements are substantial and depend on clinical progress, collaboration milestones, and potential new product candidates. The company acknowledges the need for additional funding and may seek it through equity offerings, debt financings, or further collaborations. Major risk factors include dependence on product candidate success (rinvatercept and elritercept), clinical trial delays or failures, intense competition, intellectual property protection, and the need for regulatory approvals. The Takeda collaboration is a significant source of potential future revenue but also introduces dependency on a partner for elritercept's development and commercialization outside China.